Brief: United Laboratories International Updates On Piperacillin Sodium And Tazobactam Sodium For Injection
26/07/2023 11:29
July 26 (Reuters) - United Laboratories International
Holdings Ltd 3933.HK :
* UPDATED INFORMATION ON GROUP'S PRODUCT PIPERACILLIN SODIUM
AND
TAZOBACTAM SODIUM FOR INJECTION
* PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM FOR INJECTION ,
WITH
APPROVAL OF NMPA PASSED CONSISTENCY EVALUATION
Further company coverage: 3933.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on United Laboratories International Holdings
See all newsBrief: United Laboratories International Receives Milestone Payment From Novo
Brief: United Laboratories International Says NMPA Accepts Insulin Degludec And Liraglutide Injection Marketing Registration Application
Brief: United Laboratories International Posts HY Profit Attributable RMB 347.6 Million
China's United Laboratories half-year profit drops 82%
Brief: United Laboratories International Expects HY Net Profit RMB 340 Million